# Recombinant Human Prourokinase for Acute Ischemic Stroke in the Extended Window Selected by CT-Based Artificial Intelligence

Study · id `cardio:ct-nct07901842` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07901842](<https://clinicaltrials.gov/study/NCT07901842>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT07901842

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 826 participants.

## Technical summary

Registry record NCT07901842. Randomized; quadruple masking; primary purpose treatment. Start 2026-12-01 (anticipated); primary completion 2029-12-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 826 participants (planned count; ClinicalTrials.gov record NCT07901842, source copy `cardio:ctgov-nct07901842-2026-10-28`, retrieved 2026-10-31)
- Planned start: 2026-12-01 (anticipated) (ClinicalTrials.gov record NCT07901842, source copy `cardio:ctgov-nct07901842-2026-10-28`, retrieved 2026-10-31)
- Primary completion: 2029-12-01 (anticipated) (ClinicalTrials.gov record NCT07901842, source copy `cardio:ctgov-nct07901842-2026-10-28`, retrieved 2026-10-31)
- Completion: 2030-06-01 (anticipated) (ClinicalTrials.gov record NCT07901842, source copy `cardio:ctgov-nct07901842-2026-10-28`, retrieved 2026-10-31)
- Countries: China (ClinicalTrials.gov record NCT07901842, source copy `cardio:ctgov-nct07901842-2026-10-28`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07901842-2026-10-28`, retrieved 2026-10-31)

## The registry's words

- Brief title: Recombinant Human Prourokinase for Acute Ischemic Stroke in the Extended Window Selected by CT-Based Artificial Intelligence
- Acronym: RAISE-AI
- Condition: Acute Ischemic Stroke
- Intervention (Drug): Recombinant Human Prourokinase for Injection (rhPro-UK)
- Intervention (Drug): Matching Placebo for Recombinant Human Prourokinase
- Lead sponsor: Second Affiliated Hospital, Zhejiang University, School of Medicine
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: Second Affiliated Hospital, Zhejiang University, School of Medicine (`cardio:org-second-affiliated-hospital-zhejiang-university-school-of-bfd3ac`)

## Provenance

Content hash: 762548f6c52827b745f4c0b8e64e2fe1c954646fcd7692081a54cce32b46a400
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
